Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitic and emphysematous components. In one biophysical model, the concentration of mucin on the airway surfaces is hypothesized to be a key variable that controls mucus transport in healthy persons versus cessation of transport in persons with muco-obstructive lung diseases. Under this model, it is postulated that a high mucin concentration produces the sputum and disease progression that are characteristic of chronic bronchitis.
We characterized the COPD status of 917 participants from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) using questionnaires administered to participants, chest tomography, spirometry, and examination of induced sputum. Total mucin concentrations in sputum were measured with the use of size-exclusion chromatography and refractometry. In 148 of these participants, the respiratory secreted mucins MUC5AC and MUC5B were quantitated by means of mass spectrometry. Data from chronic-bronchitis questionnaires and data on total mucin concentrations in sputum were also analyzed in an independent 94-participant cohort.
Mean (±SE) total mucin concentrations were higher in current or former smokers with severe COPD than in controls who had never smoked (3166±402 vs. 1515±152 μg per milliliter) and were higher in participants with two or more respiratory exacerbations per year than in those with zero exacerbations (4194±878 vs. 2458±113 μg per milliliter). The absolute concentrations of MUC5B and MUC5AC in current or former smokers with severe COPD were approximately 3 times as high and 10 times as high, respectively, as in controls who had never smoked. Receiver-operating-characteristic curve analysis of the association between total mucin concentration and a diagnosis of chronic bronchitis yielded areas under the curve of 0.72 (95% confidence interval [CI], 0.65 to 0.79) for the SPIROMICS cohort and 0.82 (95% CI, 0.73 to 0.92) for the independent cohort.
Airway mucin concentrations may quantitate a key component of the chronic bronchitis pathophysiologic cascade that produces sputum and mediates disease severity. Studies designed to explore total mucin concentrations in sputum as a diagnostic biomarker and therapeutic target for chronic bronchitis appear to be warranted. (Funded by the National Heart, Lung, and Blood Institute and others.)
Human airway surfaces are protected from the noxious effects of inhaled substances by a mucus clearance system that traps deposited materials and clears them from the lung.1 A failure of mucus transport, with pulmonary mucus accumulation, contributes to sputum production, airflow obstruction, and exacerbations in muco-obstructive pulmonary diseases.2-6 One such muco-obstructive disease is chronic bronchitis, also known as chronic mucus hypersecretion. Chronic bronchitis is a syndrome that is associated with cigarette smoking; it is defined by patient-reported chronic cough and sputum production and, when associated with airflow obstruction, is a component of chronic obstructive pulmonary disease (COPD). Despite the importance of mucus accumulation in the pathogenesis of chronic bronchitis, a unifying hypothesis that describes the failure of mucus flow with consequent mucus accumulation in chronic bronchitis has been lacking, and there have been no laboratory methods to confirm a diagnosis of chronic bronchitis.
The mucus that forms the protective barrier on airway surfaces is composed of water (approximately 98%), ions, globular proteins, and polymeric mucin macromolecules.1,7 The high-molecular-weight (>107 Da) mucin polymers, predominantly MUC5B and MUC5AC, provide the biophysical properties required for airway mucus transport and generate the perception of mucus as a “gel.”8 In one biophysical model (the “two-gel hypothesis”), it is posited that respiratory mucin concentrations govern the rates of mucus transport in the lung (Figure 1A).9 In this model, it is predicted that as mucin concentrations rise, a threshold concentration is exceeded, after which mucus transport ceases and adherent mucus plaques form on airway surfaces.9 Ultimately, some accumulated mucus may be expectorated as sputum. Accumulated mucus that cannot be expectorated serves as the nidus for airflow obstruction, inflammation, and intermittent infection.6,10,11 Thus, this model predicts that an increased mucin concentration will be associated with sputum production and disease severity in chronic bronchitis.
The hypothesis that total mucin concentration is a biochemical hallmark of the pathogenesis of chronic bronchitis was tested in an extensively phenotyped cohort of the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Associations between total mucin concentrations12 and sputum production, sputum characteristics, and disease severity, as indexed by means of spirometry and according to exacerbation frequency, were tested. Potential etiologic pathways for high mucin concentrations, including cigarette smoking and asthma, were also explored. Because previous data suggested that overproduction of MUC5B is associated with COPD13 and that overproduction of MUC5AC is associated with asthma,14 absolute concentrations of MUC5AC and MUC5B were measured in a SPIROMICS subgroup and the relationships of each mucin to chronic bronchitis and asthma15 were tested. Finally, the usefulness of total mucin concentrations in sputum as an objective biomarker for the diagnosis of chronic bronchitis was explored in SPIROMICS participants and participants in an independent cohort.
SPIROMICS was an observational study that examined COPD in 2981 participants who were recruited into four strata: controls who had never smoked cigarettes, current or former cigarette smokers without airflow obstruction, current or former cigarette smokers with mild-to-moderate airflow obstruction, and current or former cigarette smokers with severe airflow obstruction. Current or former smokers had a smoking history of more than 20 pack-years. Chronic bronchitis was diagnosed by means of questionnaires that were administered to participants: one questionnaire reflected the classic definition of the disorder16 (cough that is present during most days or nights, is present for 3 consecutive months of the year for 2 consecutive years, and results in phlegm production), whereas the St. George’s Respiratory Questionnaire (SGRQ)17 defined chronic bronchitis as cough and phlegm almost every day or several times a week. Emphysema was defined by the percentage of voxels in the lung field that showed attenuation of less than −950 Hounsfield units, as assessed by volumetric multidetector-row computed tomography (CT) of the lungs. Using this percentage, we classified a participant as having emphysema on the basis of normative values.18 Detailed clinical definitions are available in the Supplementary Appendix.
Sputum that was induced by inhalation of hypertonic saline was collected from 917 participants who had a forced expiratory volume in 1 second of more than 35% of the predicted value, according to the protocol19 and American Thoracic Society and European Respiratory Society standards,16 for measurement of total mucin concentrations. Induced sputum samples were placed in a buffer of guanidine (6 mol per liter),12 shipped to the SPIROMICS Biospecimen Processing Center, and stored at −4oC. The SPIROMICS protocol was approved by the participating universities, and participants provided written informed consent. (More information about the study and how to access SPIROMICS data is available at www.spiromics.org.)
Data from a questionnaire reflecting the classic definition of chronic bronchitis and data on total mucin concentrations in induced sputum were also collected from a single-site, 94-participant cohort of persons who had never smoked and current or former smokers with or without chronic bronchitis. Sputum collection and measurement technologies were identical to SPIROMICS procedures.
Total mucin concentrations in sputum were measured with the use of size-exclusion chromatography and differential refractometry. Sputum samples were injected into size-exclusion columns to isolate mucins, and effluents were passed through a laser photometer (DAWN HELEOS II, Wyatt Technology) that was coupled to a refractometer (Optilab T-rEX, Wyatt Technology). Data were analyzed with the use of ASTRA software, version 184.108.40.206 (Wyatt Technology). Sputum samples for mass-spectrometric parallel-reaction monitoring–based quantitation of MUC5B and MUC5AC were reduced, alkylated, and digested with trypsin, and six MUC5B and MUC5AC heavy-labeled peptide internal standards were spiked into sputum digests (details are provided in the Supplementary Appendix). Samples were subjected to targeted selected-ion monitoring–data-independent acquisition analysis with the use of a hybrid quadrupole Orbitrap mass spectrometer with a nanospray source (Q Exactive, Thermo Scientific). To assess salivary contamination, 86 samples were randomly selected from all groups, and salivary protein amylase levels were measured with the use of a label-free proteomics approach.20
Statistical analyses were performed with the use of SAS software, version 9.4 (SAS Institute). Total mucin, MUC5B, and MUC5AC concentrations were normalized through natural-log transformations. Analyses of variance were used to test the effects of categorical variables on total mucin, MUC5B, and MUC5AC concentrations. Pairwise comparisons between individual groups were adjusted with the Tukey–Kramer method. No adjustments for multiple testing were made. All tests were two-sided, and a P value of 0.05 or less was considered to indicate statistical significance. Data are presented as box plots, with bar graphs presented in the Supplementary Appendix. The analysis of the usefulness of sputum mucin for the diagnosis of chronic bronchitis used receiver-operating-characteristic (ROC) curve techniques. Additional details about study design, clinical definitions, methods, and statistical analysis are provided in the Supplementary Appendix.
The selection of participants from the entire SPIROMICS cohort for measurement of total mucin concentration is described in Figure S1 in the Supplementary Appendix. Characteristics of the 917 participants in whom total mucin concentration was measured are shown in Table 1, and Table S1A through S1C in the Supplementary Appendix. Characteristics of the subgroup of 148 participants in whom absolute concentrations of MUC5B and MUCAC were measured are shown in Table S1B and S1D in the Supplementary Appendix. Characteristics of the 94-participant, single-site cohort are shown in Table S1E in the Supplementary Appendix.
Total Mucin Concentrations and Phlegm Production and Quality
We first tested the relationships predicted by the two-gel hypothesis between total mucin concentrations in sputum and phlegm production and properties (Figure 1A). Total mucin concentrations in sputum were higher in current or former smokers in SPIROMICS who reported phlegm production than in controls who had never smoked or current or former smokers with no phlegm production (Figure 1B), findings consistent with the two-gel hypothesis. The relationship between mucin concentration and phlegm production remained significant after adjustment for smoking status, asthma status, and frequency of respiratory exacerbations (Table S2 in the Supplementary Appendix). Associations were also observed between total mucin concentrations and the mucoid, gel-like appearance of sputum and the numbers of gel-like plugs in sputum (Fig. S3 in the Supplementary Appendix).
Salivary contamination of sputum can bias measurements of mucin concentration. However, mass-spectroscopic analyses of salivary amylase revealed no significant between-group differences in amylase values and no correlations between amylase levels and mucin levels (Fig. S4 in the Supplementary Appendix).
Total Mucin Concentrations and Disease Status
We next tested relationships predicted by the two-gel hypothesis between total mucin concentration and disease progression (i.e., increase in severity of chronic bronchitis). Total mucin concentrations were associated with airflow obstruction as indexed by the spirometric criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD; www.goldcopd.org) (Figure 1C). For example, the mean (±SE) total mucin concentration was 3166±402 μg per milliliter in current or former smokers with a GOLD stage of 3 (indicating severe COPD) and 1515±152 μg per milliliter in controls who had never smoked. The association between mucin concentrations and GOLD status–defined airflow obstruction remained significant when the use of inhaled bronchodilator and glucocorticoid treatments was included in analysis-of-variance models (P=0.001). Relationships between total mucin concentrations and prospective exacerbation frequencies revealed that mucin concentrations were higher in SPIROMICS participants who had exacerbations than in those who had no exacerbations (≥2 exacerbations per year, 4194±878 μg per milliliter; >0 to <2 exacerbations per year, 2848±171 μg per milliliter; and 0 exacerbations, 2458±113 μg per milliliter) (Figure 1D). Similar associations were observed for exacerbations requiring interactions with health care providers (Fig. S5 in the Supplementary Appendix).
Effect of Exposure to Cigarette Smoke and Asthma on Total Mucin Concentrations
Laboratory data suggest that exposure to cigarette smoke decreases the hydration of airway surfaces and stimulates mucin production, both of which are predicted to increase mucin concentrations (Figure 1A).11,21-23 In the SPIROMICS cohort, a history of cigarette use, both past and current, was significantly associated with total mucin concentration (Figure 2A).
On the basis of reports that asthma is associated with mucin hypersecretion,1,24 relationships between a diagnosis of current asthma and total mucin concentration were tested. Approximately 15% of the current or former smokers in the SPIROMICS cohort reported current asthma (Table S1C in the Supplementary Appendix), and those participants had higher total mucin concentrations than controls who had never smoked (Figure 2B). The influence of asthma on total mucin concentration was maintained after adjustment for a history of cigarette use (P=0.002). Similar relationships were observed for a diagnosis of asthma in childhood (Fig. S7 in the Supplementary Appendix). The total mucin concentrations of SPIROMICS participants were not significantly associated with asthma biomarkers, including sputum eosinophils, blood eosinophils, or blood IgE (Fig. S8 in the Supplementary Appendix).
Sensitivity Analyses Based on Extremes of Total Mucin Concentrations
We performed sensitivity analyses that examined current or former smokers with the lowest total mucin concentrations (lowest quartile), those with normal concentrations (interquartile range), and those with the highest concentrations (highest quartile). These analyses also showed that total mucin concentrations were related to phlegm production and disease severity (Table S3 in the Supplementary Appendix).
Absolute Concentrations of MUC5B and MUC5AC
Two observations emerged from analyses of the contribution of the two secreted airway mucins to total mucin concentration. First, MUC5B was the dominant secreted mucin in control participants, with mean (±SE) concentrations approximately 10 times those of MUC5AC (108±20 vs. 10±4 pmol per milliliter) (Figure 3A and 3B). Second, MUC5B concentrations increased proportionately with greater severity of COPD (by a factor of approximately 3, to 296±65 pmol per milliliter in current or former smokers with severe COPD), whereas MUC5AC concentrations increased disproportionately (by a factor of >10, to 108±31 pmol per milliliter in current or former smokers with severe COPD) (Figure 3A and 3B). The mean (±SE) ratio of MUC5AC concentration to MUC5B concentration was significantly higher in current or former smokers with mild-to-moderate COPD than in controls who had never smoked (ratio, 0.5±0.1 vs. 0.1±0.04), but MUC5B remained the predominant mucin at all levels of disease severity (Fig. S10A in the Supplementary Appendix).
Relationships among MUC5AC Concentrations, Cigarette Smoking, and Asthma
To assess whether MUC5AC may be a biomarker for asthma in the population of cigarette smokers with COPD, relationships among cigarette smoking, asthma, and MUC5AC concentrations were investigated. The absolute concentration of MUC5AC and the ratio of MUC5AC concentration to MUC5B concentration were higher among current smokers than among controls who had never smoked (Fig. S10B and S10C in the Supplementary Appendix). This association persisted when participants with asthma were removed from the analysis (Fig. S10D in the Supplementary Appendix) and when asthma history was analyzed as a covariate (P<0.001 for MUC5AC and P=0.001 for the ratio of MUC5AC to MUC5B). In contrast, participants with current asthma or a childhood diagnosis of asthma did not have significantly higher MUC5AC concentrations than those who had never received a diagnosis of asthma (Fig. S10E in the Supplementary Appendix), and participants with high MUC5AC concentrations did not have significantly higher levels of sputum eosinophils or blood IgE than those with normal MUC5AC concentrations (Fig. S11 in the Supplementary Appendix).
Relationships among Mucin Concentrations and Diagnosis of Chronic Bronchitis
The observations suggesting that total mucin concentrations are linked to the pathophysiologic basis of chronic bronchitis raised the possibility that mucin concentrations may be an objective biomarker for chronic bronchitis. Total mucin concentrations in sputum were significantly higher in participants with either classically defined or SGRQ-defined chronic bronchitis than in those without chronic bronchitis (Figure 4A), as were MUC5B and MUC5AC concentrations (Fig. S13 in the Supplementary Appendix).
The associations between mucin concentration and a diagnosis of chronic bronchitis were tested in additional analyses. First, on the basis of data indicating that mucins are produced by airways, not alveoli, the hypothesis that the chronic bronchitic component rather than the emphysematous component of COPD dominated total mucin concentrations in sputum was tested. Participants with classically defined or SGRQ-defined chronic bronchitis, with or without CT-defined emphysema, had higher mucin concentrations than participants without chronic bronchitis, with or without emphysema (Fig. S14 in the Supplementary Appendix). Second, a recent study showed that symptoms, including phlegm production, in smokers with normal findings on spirometry identified a population with a chronic bronchitis–like phenotype (e.g., respiratory exacerbations and activity limitation).25 In our study, among current or former smokers with normal spirometric values, those with symptoms had higher total mucin concentrations than those without symptoms (Fig. S15 in the Supplementary Appendix).
Finally, the sensitivity and specificity of total mucin concentration in sputum as a biomarker for chronic bronchitis were explored in both the SPIROMICS and independent cohorts. With the use of data on SPIROMICS participants with classically defined chronic bronchitis and healthy controls who had never smoked (Figure 4A), the area under the ROC curve (AUC) for total mucin concentrations versus a diagnosis of classically defined chronic bronchitis was 0.72 (95% confidence interval [CI], 0.65 to 0.79) (Figure 4B). Data on participants in the independent cohort (those with classically defined chronic bronchitis and healthy controls who had never smoked) yielded an AUC of 0.82 (95% CI, 0.73 to 0.92) (Figure 4B). Similar relationships were observed when smokers without airflow obstruction were added to the control groups (Fig. S16 in the Supplementary Appendix). ROC analyses were also performed with respect to the entire SPIROMICS cohort (AUC, 0.62; 95% CI, 0.58 to 0.67) (Figure 4B, and Fig. S17 in the Supplementary Appendix).
Chronic bronchitis is defined symptomatically by chronic mucus production and pathologically by airway inflammation, mucous-cell metaplasia and hyperplasia, and mucus plugging.6,26 Clinically, the presence of the chronic-bronchitis phenotype (as compared with its absence) is associated with an accelerated loss of lung function and an increased frequency of COPD exacerbations.3-5,27,28
The two-gel hypothesis predicts that a high mucin concentration is the hallmark of the failed mucus transport and intrapulmonary mucus accumulation that are central to the pathogenesis of chronic bronchitis.9 This hypothesis posits that there are two hydrogels on the airway surface (i.e., the mucus layer and the periciliary layer) that compete for hydration as a function of their relative osmotic pressures. Because concentrated mucins repel one another, the mucin contribution to osmotic pressure does not have a linear relationship with concentration but scales to more than the second power of concentration.9 The periciliary layer is composed of membrane-tethered mucins and other glycoconjugates and, in healthy persons, is the more concentrated hydrogel and functions as a well-hydrated lubricant surface. In persons with chronic bronchitis, the concentration of secreted mucins in the mucus layer increases, reflecting increased mucin secretion, reduced hydration of airway surfaces, or both.11,21,22 When mucus layer concentrations and osmotic pressures exceed those of the periciliary layer (i.e., the threshold value), the mucus layer compresses the periciliary layer and produces mucus stasis and adhesion.10 Hence, we predicted that mucin concentration is the variable underlying the formation of the intraluminal mucus plaques that are expectorated with cough.
Data from the SPIROMICS cohort were consistent with this prediction. High total mucin concentrations were associated with both patient-reported phlegm production and the gel-like (mucoid) properties of the expectorated material. High total mucin concentrations were also associated with both the classic and the SGRQ definitions of chronic bronchitis, findings consistent with the inclusion of phlegm production in these definitions. High mucin concentrations were also associated with symptom-based evidence of airway disease (including phlegm) in the absence of airflow obstruction.25
The adherent intrapulmonary mucus that is not clearable by cough is predicted to contribute to airflow obstruction and exacerbation frequency in COPD (Figure 1A). Increases in the degree of GOLD status–defined airflow obstruction were observed as a function of increased mucin concentrations in SPIROMICS participants. Increased mucin concentrations were also associated with increased prospective exacerbation frequencies. Because exacerbation frequency predicts the degree of airflow obstruction,5 high total mucin concentrations may contribute to the loss of lung function in COPD through both intraluminal mucus obstruction and increased exacerbation frequencies.
The SPIROMICS cross-sectional sputum analyses allowed testing of associations, but not mechanistic links, between mucin concentration and the pathogenesis or severity of chronic bronchitis. It should be noted that previous studies involving participants with chronic bronchitis related an increase in mucus concentration to a decrease in mucociliary clearance, as predicted by the two-gel model.29 The hypothesis that mucin concentration drives the pathogenesis of chronic bronchitis is also consistent with data from studies involving animal models, which have shown that dehydration of airway surfaces and mucin hyperconcentration produced the pathologic changes underlying COPD-like lung disease.10 Consequently, we postulate that mucin concentration may quantitate the severity of a disease-causing pathway in chronic bronchitis and COPD.
The SPIROMICS data showed that having a history of cigarette use or having ever received a diagnosis of asthma was associated with high total mucin concentrations, findings consistent with previous in vitro, animal-model, and clinical studies.14,21,30 Total mucin concentrations did not return to normal values in former smokers, a finding consistent with the persistence of airway inflammation after smoking cessation.31,32 The association between asthma history and high total mucin concentrations suggests that mucin concentration may be a common pathway contributing to the worse outcomes in persons with the asthma–COPD overlap syndrome than in persons with either disease alone.33
With respect to the contributions of the two secreted mucins to disease pathogenesis, the increase in MUC5B concentration with disease severity is consistent with reports of MUC5B predominance in COPD.13 However, the disproportionate increase in MUC5AC concentrations with disease severity was striking. The elevation in MUC5AC concentrations was dominated by associations with cigarette-smoking status rather than asthma history or asthma biomarkers. This finding is consistent with a lower predictive power of asthma biomarkers in participants with asthma who smoke than in those who do not smoke34 and the dominance in this population of non–type 2 helper T-cell pathways that regulate MUC5AC expression.35 Practically, MUC5AC levels may not help define the asthma–COPD overlap syndrome in a SPIROMICS-like population with COPD.
The associations between total mucin concentration and the pathogenesis of chronic bronchitis suggest that this metric may be a quantitative biomarker for chronic bronchitis. Total mucin concentrations in sputum were associated with a diagnosis of chronic bronchitis based on each of the two types of self-report questionnaires: the questionnaire reflecting the classic definition of chronic bronchitis and the SGRQ. The ROC curves for total mucin concentration in SPIROMICS participants with a questionnaire-based diagnosis of chronic bronchitis versus control participants yielded a “fair” outcome (AUC, 0.72). A similar analysis performed in an independent, single-site cohort provided a “good” outcome (AUC, 0.82). The congruence of ROC outcomes argues for the usefulness of this measure, but the lower AUC for SPIROMICS participants suggests that variability among sites may be substantial. Future studies to test airway mucin concentrations as a diagnostic and prognostic biomarker for chronic bronchitis, as compared with questionnaire-based and airway biopsy–based metrics for the disease, appear to be warranted; such studies should include younger smokers at risk for COPD.36
Our results have therapeutic implications for chronic bronchitis. Higher total mucin concentrations (as compared with lower concentrations) were associated with asthma and exposure to cigarette smoke, suggesting that targeting upstream components of these pathways to inhibit MUC5B and MUC5AC production may be useful. Reports that exposure to hypertonic saline diluted mucin concentrations in sputum and accelerated mucus clearance in the short term among participants with chronic bronchitis suggest that therapies designed to hydrate airway surfaces and reduce mucin concentrations may also be effective.21
In conclusion, airway mucin concentrations describe a potential disease-causing, chronic-bronchitis pathway that is associated with sputum production and disease severity. If replicated, our results suggest that airway mucin concentrations may serve as a biomarker for the confirmation of the diagnosis of chronic bronchitis and the development of therapeutics for the disorder.
Funding and Disclosures
This SPIROMICS ancillary study is supported primarily by a grant (R01HL110906, to Dr. Kesimer) from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health under the NHLBI Ancillary Studies in Clinical Trials program. This study was also partially supported by grants R01HL103940, P50HL120100, and P01HL110808 from the NHLBI. This study used sputum samples and data collected through SPIROMICS, which was supported by contracts (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C) from the NHLBI; these contracts were supplemented by contributions made through the Foundation for the National Institutes of Health from AstraZeneca, Bellerophon Therapeutics, Boehringer Ingelheim Pharmaceuticals, Chiesi Farmaceutici, Forest Research Institute, GlaxoSmithKline, Grifols Therapeutics, Ikaria, Novartis Pharmaceuticals, Nycomed, Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceutical.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Dr. Kesimer and Ms. Ford contributed equally to this article.
We thank the SPIROMICS participants and participating physicians, investigators, and staff for making this research possible.
1. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010;363:2233-2247
2. Fletcher CM. The natural history of chronic bronchitis and emphysema: an eight-year study of early chronic obstructive lung disease in working men in London. Oxford, United Kingdom: Oxford University Press, 1976.
3. Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011;140:626-633
4. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996;153:1530-1535
5. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852
6. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-721
7. Kesimer M, Kirkham S, Pickles RJ, et al. Tracheobronchial air-liquid interface cell culture: a model for innate mucosal defense of the upper airways? Am J Physiol Lung Cell Mol Physiol 2009;296:L92-L100
8. Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol 2008;70:459-486
9. Button B, Cai LH, Ehre C, et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012;337:937-941
10. Livraghi-Butrico A, Grubb BR, Wilkinson KJ, et al. Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. Mucosal Immunol 2017;10:395-407
11. Rogers DF. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care 2007;52:1134-1146
12. Henderson AG, Ehre C, Button B, et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J Clin Invest 2014;124:3047-3060
13. Kirkham S, Kolsum U, Rousseau K, Singh D, Vestbo J, Thornton DJ. MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:1033-1039
14. Bonser LR, Zlock L, Finkbeiner W, Erle DJ. Epithelial tethering of MUC5AC-rich mucus impairs mucociliary transport in asthma. J Clin Invest 2016;126:2367-2371
15. Kumbhare S, Pleasants R, Ohar JA, Strange C. Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States. Ann Am Thorac Soc 2016;13:803-810
16. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978;118:1-120
17. Kim V, Crapo J, Zhao H, et al. Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene. Ann Am Thorac Soc 2015;12:332-339
18. Hoffman EA, Ahmed FS, Baumhauer H, et al. Variation in the percent of emphysema-like lung in a healthy, nonsmoking multiethnic sample: the MESA Lung Study. Ann Am Thorac Soc 2014;11:898-907
19. Couper D, LaVange LM, Han M, et al. Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax 2014;69:491-494
20. Kesimer M, Cullen J, Cao R, et al. Excess secretion of gel-forming mucins and associated innate defense proteins with defective mucin un-packaging underpin gallbladder mucocele formation in dogs. PLoS One 2015;10:e0138988-e0138988
21. Clunes LA, Davies CM, Coakley RD, et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 2012;26:533-545
22. Dransfield MT, Wilhelm AM, Flanagan B, et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 2013;144:498-506
23. Borchers MT, Wert SE, Leikauf GD. Acrolein-induced MUC5ac expression in rat airways. Am J Physiol 1998;274:L573-L581
24. Lachowicz-Scroggins ME, Yuan S, Kerr SC, et al. Abnormalities in MUC5AC and MUC5B protein in airway mucus in asthma. Am J Respir Crit Care Med 2016;194:1296-1299
25. Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 2016;374:1811-1821
26. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653
27. Kim V, Zhao H, Boriek AM, et al. Persistent and newly developed chronic bronchitis are associated with worse outcomes in chronic obstructive pulmonary disease. Ann Am Thorac Soc 2016;13:1016-1025
28. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003;41:46s-53s
29. Anderson WH, Coakley RD, Button B, et al. The relationship of mucus concentration (hydration) to mucus osmotic pressure and transport in chronic bronchitis. Am J Respir Crit Care Med 2015;192:182-190
30. Innes AL, Woodruff PG, Ferrando RE, et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006;130:1102-1108
31. Lapperre TS, Postma DS, Gosman MM, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax 2006;61:115-121
32. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005;26:835-845
33. Postma DS, Rabe KF. The asthma–COPD overlap syndrome. N Engl J Med 2015;373:1241-1249
34. Gray T, Coakley R, Hirsh A, et al. Regulation of MUC5AC mucin secretion and airway surface liquid metabolism by IL-1beta in human bronchial epithelia. Am J Physiol Lung Cell Mol Physiol 2004;286:L320-L330
35. O’Donnell RA, Richter A, Ward J, et al. Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax 2004;59:1032-1040
36. Allinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JA. The presence of chronic mucus hypersecretion across adult life in relation to chronic obstructive pulmonary disease development. Am J Respir Crit Care Med 2016;193:662-672
Citing Articles (175)
- Figure 1. Associations between Total Mucin Concentrations and Phlegm Production and Disease Severity in Chronic Obstructive Pulmonary Disease (COPD).
- Table 1. Characteristics of Total Mucin Concentration Study as Compared with the Entire SPIROMICS Cohort at Baseline.
- Figure 2. Association between Potential Etiologic Pathways and Total Mucin Concentrations in Sputum.
- Figure 3. Absolute Concentrations of MUC5B and MUC5AC and Disease Severity.
- Figure 4. Total Mucin Concentration and Diagnosis of Chronic Bronchitis.
Original ArticleJun 23 Original ArticleJun 23 Original ArticleJun 23